New Immunotherapy Increases Brain Cancer Patient Survival Time – AJMC.com Managed Markets Network
New Immunotherapy Increases Brain Cancer Patient Survival TimeAJMC.com Managed Markets NetworkTocagen, a cancer-selective gene therapy company, is developing a new immunotherapy for patients with recurrent brain cancer called Toca 511 and Toca FC, refe… Continue reading
